Dr Reddy's Laboratories has entered into an exclusive agreement with Takeda Pharmaceutical Company to distribute QDENGA, India's first approved dengue vaccine, in the private market. Subject to regulatory processes, the vaccine is expected to become available in the first half of 2027
India's first dengue vaccine, QDENGA, is set to enter the market in the first half of 2027 under an exclusive partnership between Takeda and Dr Reddy's Laboratories. The agreement will facilitate private-market distribution and awareness ahead of the commercial rollout
India has granted market authorisation to Takeda Biopharmaceuticals’ dengue vaccine QDENGA, making it the country’s first approved vaccine for dengue prevention. The approval by CDSCO follows extensive global and Indian clinical trials confirming its safety and efficacy.
India has approved its first dengue vaccine, QDENGA, for individuals aged 4 to 60 years. The DCGI clearance allows vaccination without pre-screening and marks a major step in strengthening dengue prevention alongside surveillance, vector control and public health measures.
